Ohio State University is serious about clinical and medical research. With $268.5 million in OSU College of Medicine funding alone, Buckeye investigators are securing research grants and deals from multiple sources from the national institutes of Health to state grants and industry contracts. In recent years, this venerable Midwestern institution has participated in over 3,000 clinical trials. Breadth and depth with scale makes this research center a must to consider for major partnerhsips.
The Buckeyes rank 42nd in the nation when it comes to NIH funding for research at $137.9 million. But that is only part of the story. Funding sources are myriad and breakthroughs many including examples below.
Recent Buckeye Clinical Research Breakthroughs
As was recently reported in the Columbus Monthly, Ohio State University is a formidable research leader in the United States and should be considered by research funding sources as a go-to research center.
The first-ever human trial of an novel anticancer vaccine, called B-Vaxx, was led by Ohio State researcher Pravin Kaumaya, professor in the college of medicine’s department of obstetrics and gynecology. Through this research, the team was able to demonstrate that patients with metastatic or recurrent solid tumors that overexpress the HER-2 protein had a stronger immune response than they did to current treatments. This can imply that B-Vaxx may be superior to killing tumor cells in a range of aggressive cancers.
Ohio State University investigators are pursuing promising advanced gene therapies for Parkinson’s and other neurodegenerative disease. For example, Dr. Krystof Bankiewicz and Dr. Russell Lonser, chair of OSU’s department of neurology surgery, the team seek to find treatments and hopefully a gene-based cure someday. A joint gene therapy effort involving UniQure with the help of a private-public collaboration involving Dr. Bankiewicz. Previously at UCSF, Bankiewicz moved to OSU—both OSU and UCSF are collaborating on a joint effort called Brain Neu Bio.
OSU is leading the way with six clinical trials involving gene therapy and its effects on neurodegenerative disease—from Parkinson’s, Alzheimer’s, Huntington’s and more, reports Columbus Monthly. OSU has been involved with studies involving pediatric patients that has achieved FDA Fast-Track status.
OSU Buckeye researchers are leading the way with deep brain stimulation clinical research on Alzheimer’s patients. Dr. Douglas Scharre, professor of neurology and clinical psychology at OSU’s Center for Cognitive and Memory Disorders and its Center for Neuromodulation leads the way.
Dr. Ahmet Kilic, former OSU associate professor of cardiac surgery led a pilot study on the efficacy of the Watchman, a tiny parachute-like device which is implanted into the heart to regulate the heartbeat of those who suffer from atrial fibrillation. (Kilic now directs heart transplantation and mechanical circulatory at Johns Hopkins Medicine).
Ohio State University
Founded in 1870, this public research university based in Columbus, Ohio, was originally known as the Ohio Agricultural and Mechanical College. The Ohio State University main campus in Columbus has grown to the third-largest university campus in the United States. Additional regional campuses are managed in Lima, Mansfield, Marion, Neward and Wooster.
With an endowment of $5.2 billion, OSU has a total of approximately 68,000 students. It is part of the University System of Ohio.
OSU Wexler Medical Center: Research Hub
OSU’s Wexler Medical Center is a major hub of clinical research not only in the Midwest but also nationwide. The multidisciplinary academic medical center has for 26 consecutive years been recognized in the “Best Hospitals” U.S. News & World Report rankings. In 2018, U.S. U.S. News & World Report ranked 10 Ohio State Wexner Medical Center specialties. Moreover, in 2018 it was named the best hospital in central Ohio.
The Center for Clinical Translational Science (CCTS) is a collaboration of the Ohio State University, The Ohio State University Wexner Medical Center and Nationwide Children’s Hospital—all funded by a Clinical and Translational Science Award from the National Institutes of Health.
OSU’s Arthur G. James Hospital and Richard J. Solove Research Institute (OSUCCC—James) is an NCI-designated Comprehensive Cancer Center with a vision to create a cancer-free world, one person, one discovery at a time. The OSUCCC—James is the only cancer program in the United States that features a National Cancer Institute-designated comprehensive cancer center aligned with a nationally ranked academic medical center and a freestanding cancer hospital on the campus of one of the nation’s largest public universities.